(Updated - July 16, 2019 6:43 AM EDT)

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.58, $0.12 better than the analyst estimate of $2.46. Revenue for the quarter came in at $20.6 billion versus the consensus estimate of $20.29 billion.

"We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world."

GUIDANCE:

Johnson & Johnson sees FY2019 EPS of $8.53-$8.63, versus the consensus of $8.60. Johnson & Johnson sees FY2019 revenue of $80.8-81.6 billion, versus the consensus of $81.22 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.